Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response ((,)✰✰)

Human cytomegalovirus (HCMV) is a major cause of disability in congenitally infected infants and in the immunosuppressed. There is currently no licensed prophylactic HCMV vaccine. The HCMV envelope glycoprotein B (gB) is considered a major vaccine target antigen based on its critical role in mediati...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Vaccine
Main Authors: Cui, Xinle, Cao, Zhouhong, Wang, Shuishu, Lee, Ronzo B., Wang, Xiao, Murata, Haruhiko, Adler, Stuart P., McVoy, Michael A., Snapper, Clifford M.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6556890/
https://ncbi.nlm.nih.gov/pubmed/30082162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2018.07.056
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki